Dr. Michael Rowley Inducted into the Hall of Fame of ACS Division of Medicinal Chemistry

Dr. Michael  Rowley, Senior Vice President, Pharmaron Drug Discovery Services Europe, has been inducted into the Hall of Fame of ACS Division of Medicinal Chemistry at the Washington ACS meeting. The induction ceremony was held on Tuesday, August 22, 2017 at the Washington Convention Center.

Dr. Michael Rowley, together with other three medicinal chemists, were inducted into Hall of Fame, including Stanley T. Crooke , Gunda Georg, and Michael J. Sofia.
We congratulate Dr. Michael Rowley on receiving this honorary induction award in recognition of his great contribution to the medicinal chemistry.
 
About Dr. Michael Rowley

Dr. Mike Rowley joined Pharmaron in March 2017, as Senior Vice President, Drug Discovery Services Europe. He studied in Cambridge, U.K., receiving his MA and PhD. He spent two years as a postdoc with Yoshito Kishi at Harvard University, completing the total synthesis of Ophiobolin C. In 1988, he joined Merck Sharp and Dohme in the UK as a medicinal chemist, in various neuroscience projects. In 2000, Mike moved to become responsible for Medicinal Chemistry and DMPK at the Istituto di Ricerche di Biologia Molecolare (IRBM – MSD’s site in Rome), working in the areas of antivirals and cancer. It was during this time that the group in Rome, with the MRL site West Point, discovered raltegravir (Isentress™), the first-in-class inhibitor of HIV integrase. This was followed by IRBM’s discoveries of grazoprevir, an HCV protease inhibitor approved in a combination therapy as Zepatier™ for hepatitis C virus infection and of niraparib (Zejula™), a PARP inhibitor used for ovarian cancer. Following the closure of the IRBM, he joined AstraZeneca in Mölndal, Sweden. Mike led work in lead generation and optimization, computational chemistry and scale up covering cardiovascular, gastrointestinal, diabetes and obesity projects. He returned to MSD in 2012 as Associate Scientific Vice President, based in Luzern, Switzerland. Mike returned to the UK in 2016, and joined Pharmaron in 2017. He has published over 100 papers and 40 patent applications. Mike is a Fellow of the Royal Society of Chemistry and received the ACS Heroes of Chemistry award in 2013.